Related references
Note: Only part of the references are listed.CD19 CAR T cell therapy effective for systemic lupus erythematosus
J. Gelfand
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Richard A. Furie et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
David Jayne et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
B cells in systemic lupus erythematosus
Franziska Szelinski et al.
CURRENT OPINION IN RHEUMATOLOGY (2022)
Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms
Stefanie Steiger et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)
Renal mTORC1 activation is associated with disease activity and prognosis in lupus nephritis
Zhaomin Mao et al.
RHEUMATOLOGY (2022)
The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus
Thomas Morel et al.
RHEUMATOLOGY (2022)
Long-Term Results of Triple Immunosuppression With Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis
Desmond Y. H. Yap et al.
KIDNEY INTERNATIONAL REPORTS (2022)
Biological impact of iberdomide in patients with active systemic lupus erythematosus
Peter E. Lipsky et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
TLR7 gain-of-function genetic variation causes human lupus
Grant J. Brown et al.
NATURE (2022)
Interferon blockade in lupus: effects on antiviral immunity
Stefanie Steiger et al.
NATURE REVIEWS NEPHROLOGY (2022)
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus
Joan T. Merrill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis A Randomized Clinical Trial
Zhaohui Zheng et al.
JAMA NETWORK OPEN (2022)
Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans
Isaac T. W. Harley et al.
FRONTIERS IN IMMUNOLOGY (2022)
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Andreas Mackensen et al.
NATURE MEDICINE (2022)
Update on the diagnosis and management of systemic lupus erythematosus
Antonis Fanouriakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Expanding the Role of Complement Therapies: The Case for Lupus Nephritis
Nicholas L. Li et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Murine myeloid cell MCPIP1 suppresses autoimmunity by regulating B-cell expansion and differentiation
Ewelina Dobosz et al.
DISEASE MODELS & MECHANISMS (2021)
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Brad H. Rovin et al.
LANCET (2021)
Impacts of FcγRIIB and FcγRIIIA gene polymorphisms on systemic lupus erythematous disease activity index
Mansoor Karimifar et al.
BMC RESEARCH NOTES (2021)
Variants in BANK1 are associated with lupus nephritis of European ancestry
Karin Bolin et al.
GENES AND IMMUNITY (2021)
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
Dimitrios Mougiakakos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus
Sarfaraz A. Hasni et al.
NATURE COMMUNICATIONS (2021)
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Jing He et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond
Erkan Demirkaya et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis
Chi Chiu Mok et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Lupus nephritis
Hans-Joachim Anders et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Independent Replication on Genome-Wide Association Study Signals IdentifiesIRF3as a Novel Locus for Systemic Lupus Erythematosus
Feixia Zhang et al.
FRONTIERS IN GENETICS (2020)
Mapping systemic lupus erythematosus heterogeneity at the single-cell level
Djamel Nehar-Belaid et al.
NATURE IMMUNOLOGY (2020)
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus
Lennard Ostendorf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cathelicidin LL-37: A new important molecule in the pathophysiology of systemic lupus erythematosus
Alejandro Moreno-Angarita et al.
JOURNAL OF TRANSLATIONAL AUTOIMMUNITY (2020)
Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy
Matthew Baker et al.
RMD OPEN (2020)
Synergistic activation of NF-κB by TNFAIP3 (A20) reduction and UBE2L3 (UBCH7) augment that synergistically elevate lupus risk
Taehyeung Kim et al.
ARTHRITIS RESEARCH & THERAPY (2020)
The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target
Tomohiro Koga et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
Effect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis
Chenzhu Zhang et al.
CLINICAL SCIENCE (2019)
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
Martin Aringer et al.
ARTHRITIS & RHEUMATOLOGY (2019)
ADAR1 and PKR, interferon stimulated genes with clashing effects on HIV-1 replication
Roman Radetskyy et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2018)
Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
Zhi-Wei Lai et al.
LANCET (2018)
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
Daniel J. Wallace et al.
LANCET (2018)
Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis
C-B Choi et al.
LUPUS (2018)
Genetic contributions to lupus nephritis in a multi-ethnic cohort of systemic lupus erythematous patients
Cristina M. Lanata et al.
PLOS ONE (2018)
The RNA-Specific Adenosine Deaminase ADAR1 Inhibits Human Protein Kinase R Activation
Tony T. Wang et al.
VIRAL IMMUNOLOGY (2018)
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study
Joan T. Merrill et al.
ARTHRITIS & RHEUMATOLOGY (2018)
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis
Laurence E. Cheng et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
Joan T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
An evaluation of voclosporin for the treatment of lupus nephritis
Fang En Sin et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Recruitment of calcineurin to the TCR positively regulates T cell activation
Debjani Dutta et al.
NATURE IMMUNOLOGY (2017)
Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction
Yasuko Furumoto et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Detection of interferon alpha protein reveals differential levels and cellular sources in disease
Mathieu P. Rodero et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Multitarget Therapy for Maintenance Treatment of Lupus Nephritis
Haitao Zhang et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis
Pragnesh Mistry et al.
CLINICAL IMMUNOLOGY (2017)
Toll-like receptor activation in the pathogenesis of lupus nephritis
Georg Lorenz et al.
CLINICAL IMMUNOLOGY (2017)
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
J. T. Merrill et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)
Kenneth C. Kalunian et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
D. A. Isenberg et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study
Munther Khamashta et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients
Romain Banchereau et al.
CELL (2016)
T cells in Systemic Lupus Erythematosus
Abel Suarez-Fueyo et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Cytosolic DNA Sensing: The Field Narrows
Russell E. Vance
IMMUNITY (2016)
Complement in removal of the dead - balancing inflammation
Myriam Martin et al.
IMMUNOLOGICAL REVIEWS (2016)
Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years
Zachary Oaks et al.
CURRENT RHEUMATOLOGY REPORTS (2016)
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up
Chi Chiu Mok et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Ofatumumab treatment in lupus nephritis patients
Malena Loberg Haarhaus et al.
CLINICAL KIDNEY JOURNAL (2016)
Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial
Zhihong Liu et al.
ANNALS OF INTERNAL MEDICINE (2015)
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Tobias Alexander et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
CXCL13 antibody for the treatment of autoimmune disorders
Ekaterina Klimatcheva et al.
BMC IMMUNOLOGY (2015)
Clinical presentation of human C1q deficiency: How much of a lupus?
Mihaela Stegert et al.
MOLECULAR IMMUNOLOGY (2015)
Activation of cyclic GMP-AMP synthase by self-DNA causes autoimmune diseases
Daxing Gao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Complement in Lupus Nephritis: New Perspectives
Lihua Bao et al.
KIDNEY DISEASES (2015)
Immunopathology of lupus nephritis
Hans-Joachim Anders et al.
SEMINARS IN IMMUNOPATHOLOGY (2014)
Resequencing the susceptibility gene, ITGAM, identifies two functionally deleterious rare variants in systemic lupus erythematosus cases
Amy L. Roberts et al.
ARTHRITIS RESEARCH & THERAPY (2014)
End-Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1
Barry I. Freedman et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Meta-analysis Followed by Replication Identifies Loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as Associated with Systemic Lupus Erythematosus in Asians
Wanling Yang et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2013)
Lupus Nephritis and End-stage Kidney Disease
Natallia Maroz et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2013)
A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function
E. G. Kamburova et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Recent insights into the genetic basis of systemic lupus erythematosus
Ornella Josephine Rullo et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Genetic variation near IRF8 is associated with serologic and cytokine profiles in systemic lupus erythematosus and multiple sclerosis
B. S. Chrabot et al.
GENES AND IMMUNITY (2013)
ABIN1 Dysfunction as a Genetic Basis for Lupus Nephritis
Dawn J. Caster et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
The Pathogenesis of Lupus Nephritis
Maciej Lech et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE
M. A. Dooley et al.
LUPUS (2013)
A diverse array of genetic factors contribute to the pathogenesis of Systemic Lupus Erythematosus
Nicki Tiffin et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Association of STAT4 Polymorphism with Severe Renal Insufficiency in Lupus Nephritis
Karin Bolin et al.
PLOS ONE (2013)
B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
Maria J. Leandro
ARTHRITIS RESEARCH & THERAPY (2013)
Genetics and Epigenetics of Systemic Lupus Erythematosus
Patricia Costa-Reis et al.
CURRENT RHEUMATOLOGY REPORTS (2013)
Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries
Kwangwoo Kim et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
Lupus nephritis: A critical review
Andrea T. Borchers et al.
AUTOIMMUNITY REVIEWS (2012)
Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis
C. P. Lin et al.
GENES AND IMMUNITY (2012)
Cutting Edge: IL-21 Derived from Human Follicular Helper T Cells Acts as a Survival Factor for Secondary Lymphoid Organ, but Not for Bone Marrow, Plasma Cells
Beatriz Rodriguez-Bayona et al.
JOURNAL OF IMMUNOLOGY (2012)
Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis
Xiao Li et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Further Evidence of Subphenotype Association with Systemic Lupus Erythematosus Susceptibility Loci: A European Cases Only Study
Elisa Alonso-Perez et al.
PLOS ONE (2012)
The genetics of lupus: a functional perspective
Sandra G. Guerra et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial
Wei Chen et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2011)
Genetic association of PRDM1-ATG5 intergenic region and autophagy with systemic lupus erythematosus in a Chinese population
Xu-jie Zhou et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Interleukin-1 receptor-associated kinase-M suppresses systemic lupus erythematosus
Maciej Lech et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
A Systemic Lupus Erythematosus-associated R77H Substitution in the CD11b Chain of the Mac-1 Integrin Compromises Leukocyte Adhesion and Phagocytosis
Matthew MacPherson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
A20-binding inhibitor of NF-κB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein β activation and protects from inflammatory disease
Jingran Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Cytosolic DNA sensors regulating type I interferon induction
Sinead E. Keating et al.
TRENDS IN IMMUNOLOGY (2011)
The type I interferon system in the etiopathogenesis of autoimmune diseases
Lars Ronnblom
UPSALA JOURNAL OF MEDICAL SCIENCES (2011)
Differential Genetic Associations for Systemic Lupus Erythematosus Based on Anti-dsDNA Autoantibody Production
Sharon A. Chung et al.
PLOS GENETICS (2011)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Pathways: Strategies for susceptibility genes in SLE
James M. Kelley et al.
AUTOIMMUNITY REVIEWS (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
The complement system in systemic autoimmune disease
Min Chen et al.
JOURNAL OF AUTOIMMUNITY (2010)
MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-κB signaling
Jian Liang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
The Apolipoprotein L1 (APOL1) Gene and Nondiabetic Nephropathy in African Americans
Barry I. Freedman et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study
J. Zavada et al.
LUPUS (2010)
Genetic susceptibility to systemic lupus erythematosus in the genomic era
Yun Deng et al.
NATURE REVIEWS RHEUMATOLOGY (2010)
Association of TNFAIP3 interacting protein 1, TNIP1 with systemic lupus erythematosus in a Japanese population: a case-control association study
Aya Kawasaki et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Randomized, Controlled Trial of Prednisone, Cyclophosphamide, and Cyclosporine in Lupus Membranous Nephropathy
Howard A. Austin et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus
Vesela Gateva et al.
NATURE GENETICS (2009)
The role of innate immunity in autoimmune tissue injury
Ramanjaneyulu Allam et al.
CURRENT OPINION IN RHEUMATOLOGY (2008)
Successful treatment of class V+IV lupus nephritis with multitarget therapy
Hao Bao et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2008)
Rapamycin prevents the development of nephritis in lupus-pirone NZH/W F-1 mice
S. L. Lui et al.
LUPUS (2008)
A nonsynonymous functional variant in integrin-αM (encoded by ITGAM) is associated with systemic lupus erythematosus
Swapan K. Nath et al.
NATURE GENETICS (2008)
Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci
John B. Harley et al.
NATURE GENETICS (2008)
Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus
Stacy L. Musone et al.
NATURE GENETICS (2008)
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
Kirsten Neubert et al.
NATURE MEDICINE (2008)
The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A
Christian Faul et al.
NATURE MEDICINE (2008)
Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus
Kimberly E. Taylor et al.
PLOS GENETICS (2008)
Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation
Jonathan A. Deane et al.
IMMUNITY (2007)
Both Fcγ and complement receptors mediate transfer of immune complexes from erythrocytes to human macrophages under physiological flow conditions in vitro
A. L. Hepburn et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus
Sean R. Christensen et al.
IMMUNITY (2006)
Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication
Prapaporn Pisitkun et al.
SCIENCE (2006)
Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare
DJ Birmingham et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
G-rich DNA suppresses systemic lupus
PS Patole et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity
M Yoneyama et al.
JOURNAL OF IMMUNOLOGY (2005)
Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells
G Muehlinghaus et al.
BLOOD (2005)
Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response
M Odendahl et al.
BLOOD (2005)
The role of autophagy during the early neonatal starvation period
A Kuma et al.
NATURE (2004)
Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice
BF Hoyer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations
S Arce et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2004)
CR1 and CR1-like: the primate immune adherence receptors
DJ Birmingham et al.
IMMUNOLOGICAL REVIEWS (2001)
Share Paper
